Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease.
Antonio VitaleVirginia BerlengieroJurgen SotaLuisa CiarciaNicola RiccoSara BarneschiMariam MourabiGiuseppe LopalcoChiara MarzoFrancesca BellisaiFlorenzo IannoneBruno FredianiClaudia FabianiPublished in: Mediators of inflammation (2020)
CAN has shown prompt and remarkable effectiveness in controlling AOSD activity in a real-life contest, with a significant glucocorticoid-sparing effect and an excellent safety profile.